BACKGROUND: Hepatocyte growth factor activator inhibitor type 1 (HAI-1), one of the Kunitz-type serine protease inhibitors, has an important role in cancer progression through regulation of the activity of hepatocyte growth factor. HAI-1 is expressed in hepatocellular carcinoma (HCC) to various degrees. Investigation of the relationship between HAI-1 expression and clinicopathological features of HCC may contribute to improved treatment outcomes for HCC through understanding the mechanism of tumor progression or improvement in the prediction of tumor malignancy. METHODS: The study included 121 HCC patients treated surgically from 1996 to 2005. We performed immunohistological examination for HAI-1 in resected HCC specimens by use of anti-human HAI-1 monoclonal antibody. Clinicopathological features, including postoperative overall survival (OS) and disease-free survival (DFS) rates, were compared between the immunoreaction positive and negative groups. RESULTS: The immunoreaction positive group included 38 patients (31%), and the negative group included 83 patients (69%). OS and DFS rates were significantly higher in the HAI-1 negative group than in the positive group. HAI-1 positivity related to multiplicity, vascular invasion, and characteristics of advanced tumor stage. In multivariate analysis, expression of HAI-1 was a significant independent prognostic tumor factor. CONCLUSIONS: Expression of HAI-1 in HCC cells is associated with poor prognosis for HCC patients. HAI-1 may be important in HCC progression and may be a new prognostic factor for HCC.
BACKGROUND:Hepatocyte growth factor activator inhibitor type 1 (HAI-1), one of the Kunitz-type serine protease inhibitors, has an important role in cancer progression through regulation of the activity of hepatocyte growth factor. HAI-1 is expressed in hepatocellular carcinoma (HCC) to various degrees. Investigation of the relationship between HAI-1 expression and clinicopathological features of HCC may contribute to improved treatment outcomes for HCC through understanding the mechanism of tumor progression or improvement in the prediction of tumor malignancy. METHODS: The study included 121 HCC patients treated surgically from 1996 to 2005. We performed immunohistological examination for HAI-1 in resected HCC specimens by use of anti-humanHAI-1 monoclonal antibody. Clinicopathological features, including postoperative overall survival (OS) and disease-free survival (DFS) rates, were compared between the immunoreaction positive and negative groups. RESULTS: The immunoreaction positive group included 38 patients (31%), and the negative group included 83 patients (69%). OS and DFS rates were significantly higher in the HAI-1 negative group than in the positive group. HAI-1 positivity related to multiplicity, vascular invasion, and characteristics of advanced tumor stage. In multivariate analysis, expression of HAI-1 was a significant independent prognostic tumor factor. CONCLUSIONS: Expression of HAI-1 in HCC cells is associated with poor prognosis for HCC patients. HAI-1 may be important in HCC progression and may be a new prognostic factor for HCC.
Authors: W Y Lau; T W Leung; S K Ho; M Chan; D Machin; J Lau; A T Chan; W Yeo; T S Mok; S C Yu; N W Leung; P J Johnson Journal: Lancet Date: 1999-03-06 Impact factor: 79.321
Authors: A Monvoisin; V Neaud; V De Lédinghen; L Dubuisson; C Balabaud; P Bioulac-Sage; A Desmoulière; J Rosenbaum Journal: J Hepatol Date: 1999-03 Impact factor: 25.083
Authors: A D'Errico; M Fiorentino; A Ponzetto; Y Daikuhara; H Tsubouchi; C Brechot; J Y Scoazec; W F Grigioni Journal: Hepatology Date: 1996-07 Impact factor: 17.425
Authors: Jung Y Kang; Marisa Dolled-Filhart; Idris Tolgay Ocal; Baljit Singh; Chen-Yong Lin; Robert B Dickson; David L Rimm; Robert L Camp Journal: Cancer Res Date: 2003-03-01 Impact factor: 12.701
Authors: E Santoni-Rugiu; K H Preisegger; A Kiss; T Audolfsson; G Shiota; E V Schmidt; S S Thorgeirsson Journal: Proc Natl Acad Sci U S A Date: 1996-09-03 Impact factor: 11.205